CONSIDERATIONS TO KNOW ABOUT DEUCRAVACITINIB

There were no clinically substantial differences inside the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when utilised concomitantly with finerenone. Several doses of forty mg finerenone once-day by day had no clinically suitable impact on AUC or Cmax from the BCRP and OATP substrate rosuvastatin.Do no